Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither.

Blood
Richard J Jones, Michael R DeBaun

Abstract

Recently, encouraging data provided long-awaited hope for gene therapy as a cure for sickle cell disease (SCD). Nevertheless, the transient suspension of the bluebird bio gene therapy trial (clinicaltrials.gov: NCT02140554) after participants developed acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) raised concerns. Potential possibilities for these cases include busulfan, insertional mutagenesis, both, or neither. Busulfan was considered the cause in the first reported case because the transgene was not present in the AML/MDS. However, busulfan is unlikely to have contributed to the most recent case. The transgene was present in the patient's malignant cells, indicating they were infused after busulfan treatment. Several lines of evidence suggest an alternative explanation for events in the bluebird bio trial, including that SCD population studies show an increased relative, but a low absolute, risk of AML/MDS. We propose a new hypothesis: after gene therapy for SCD, the stress of switching from homeostatic to regenerative hematopoiesis by transplanted cells drives clonal expansion and leukemogenic transformation of preexisting premalignant clones, eventually resulting in AML/MDS. Evidence validating our hypothesis w...Continue Reading

References

Sep 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N J ChaoS J Forman
Jun 9, 1994·The New England Journal of Medicine·O S PlattP P Klug
Aug 10, 2000·The Journal of Clinical Investigation·O S Platt
Dec 17, 2009·The New England Journal of Medicine·Matthew M HsiehJohn F Tisdale
Oct 19, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel H Wiseman
Jul 1, 2015·British Journal of Haematology·Kenneth I Ataga, Jonathan Stocker
Mar 16, 2016·Leukemia·Lukasz P GondekChristopher D Gocke
Jun 22, 2016·Journal of the Royal Society of Medicine·Olena O SeminogMichael J Goldacre
Jan 10, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher J GibsonBenjamin L Ebert
Mar 2, 2017·The New England Journal of Medicine·Jean-Antoine RibeilMarina Cavazzana
Jul 4, 2017·American Journal of Human Genetics·Rocio Acuna-HidalgoAlexander Hoischen
Mar 16, 2018·Nature Reviews. Disease Primers·Gregory J KatoElliott P Vichinsky
Sep 3, 2018·The Lancet. Haematology·Richard J Jones, Mary M Horowitz
Dec 1, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Josu de la FuenteAdetola A Kassim
Nov 19, 2019·The Journal of Clinical Investigation·Robert A Brodsky, Michael R DeBaun
Mar 21, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Alexis Leonard, John F Tisdale

❮ Previous
Next ❯

Citations

Sep 10, 2021·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·I Thuret
Nov 18, 2021·The New England Journal of Medicine·Sandhya Kharbanda, Christopher C Dvorak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2021 Meta ULC. All rights reserved